Patents Issued in May 6, 2004
-
Publication number: 20040086475Abstract: The present invention relates to hair care compositions comprising an oxidizing agent and chelants having 1 log ⁢ ⁢ K CuL log ⁢ ⁢ K CaLType: ApplicationFiled: September 22, 2003Publication date: May 6, 2004Applicant: The Procter & Gamble CompanyInventors: Henry Drummond Boswell, Jennifer Mary Marsh, John Scott Park, Michael Andrew Olshavsky
-
Publication number: 20040086476Abstract: Described are anti-dandruff and anti-itch compositions comprising:Type: ApplicationFiled: August 19, 2003Publication date: May 6, 2004Inventors: Linda J. Flammer, Brian T. Grainger, Richard M. Boden, Carol Christensen
-
Publication number: 20040086477Abstract: Methods and kits for removing scales caused by cradle cap on the heads of infants are disclosed and include topically applying to the scalp an effective amount of a pre-treatment composition, a shampoo and a moisturizer for respective time periods sufficient to remove cradle cap. A scale-removing device is also used to help remove and loosen any scales.Type: ApplicationFiled: September 19, 2003Publication date: May 6, 2004Inventors: Wanda Richard, Rebecca Whipple, Richard Jentis
-
Publication number: 20040086478Abstract: The invention relates to a physiologically acceptable, in particular cosmetic, composition comprising at least one liquid fatty phase comprising at least one volatile solvent, the liquid fatty phase begin structured by at least one polymer with a weight-average molecular mass of less than or equal to 100 000, comprising a) a polymer backbone having hydrocarbonaceous repeat units provided with at least one heteroatom and b) optionally functionalized pendant and/or end fatty chains having from 6 to 120 carbon atoms which are bonded to these units, the liquid fatty phase and the polymer forming a physiologically acceptable medium. This composition is provided in particular in the form of a stick of lipstick, the application of which results in a notable glossy and transfer-free layer with good hold over time.Type: ApplicationFiled: December 6, 2001Publication date: May 6, 2004Inventor: Veronique Ferrari
-
Publication number: 20040086479Abstract: Crosslinkable polymers, such as dendritic macromolecules and their in vitro, in vivo, and in situ uses are disclosed. These biomaterials/polymers are likely to be an effective sealant/glue for a variety of surgical procedures where the site of the wound is not easily accessible or when sutureless surgery is desirable. Crosslinkable dendritic macromolecules can be fabricated into cell scaffold/gel/matrix of specified shapes and sizes using chemical techniques. The polymers, after being crosslinked, can be seeded with cells and then used to repair or replace organs, tissue, or bones. Alternatively, the polymers and cells can be mixed and then injected into the in vivo site and crosslinked in situ for organ, tissue, or bone repair or replacement. The crosslinked polymers provide three dimensional templates for new cell growth that is suitable for a variety of reconstructive procedures, including custom molding of cell implants to reconstruct three dimensional tissue defects.Type: ApplicationFiled: April 25, 2003Publication date: May 6, 2004Applicant: DUKE UNIVERSITYInventors: Mark W. Grinstaff, Michael A. Carnahan, Terry Kim, Nate Luman, Meredith Morgan, Michel Wathier
-
Publication number: 20040086480Abstract: Methylated polystyrene having pendant N-halamine and N-halamine precursor groups. Biocidal particles have been prepared by reacting highly crosslinked methylated polystyrene beads as starting materials with various N-halamine precursor compounds. The resulting polymer beads are halogenated with chlorine or bromine. The porous beads will be useful in disinfection applications, as well as for sanitization and controlling noxious odor when mixed with absorbent materials in items such as disposable diapers, infant swimwear, incontinence pads, bandages, sanitary napkins, pantiliners, mattress covers, shoe inserts, sponges, animal litter, carpets, and fabrics.Type: ApplicationFiled: October 31, 2002Publication date: May 6, 2004Applicant: Auburn UniversityInventors: Shelby D. Worley, Yongjun Chen
-
Publication number: 20040086481Abstract: A nucleic acid complex for delivering a nucleic acid or a derivative thereof to a cell comprises the components: A. a nucleic acid or a derivative thereof; B. a cationic polymer; and C. a preformed polyethylene glycol-cationic polymer copolymer. The complex has a conformation in which the nucleic acid or derivative thereof is condensed and wherein component C is bound to component A such that the poylethylene glycol groups of component C are located at the surface of the complex. The complexes which are stable to aggregation are useful for the delivery of nucleic acids or derivatives thereof to cells in biological systems.Type: ApplicationFiled: April 9, 2003Publication date: May 6, 2004Inventors: Martin Charles Garnett, Nicolas Andrew Jones, Benjamin James Rackstraw, Fabio Bignotti
-
Publication number: 20040086482Abstract: The present invention is directed to compositions comprising polymeric tertiary amines of urethane esters and salts thereof. The compositions are generally derived from linear or branched chain compounds of synthetic or natural origin, preferably from trialkalnolamines that have been esterified with organic acids including long chain fatty acids and reacted with diisocyanate compounds to form urethane adducts. These adducts are in turn polymerized with organic acids to form polymeric urethane ester tertiary amine salts. The compositions of the present invention may be incorporated into personal care formulations such as cosmetics, toiletries and shampoos and into detergents to improve or modify at least two of the characteristics of such formulations.Type: ApplicationFiled: November 1, 2002Publication date: May 6, 2004Inventors: Albert Zofchak, John Obeji
-
Publication number: 20040086483Abstract: A method of treating rheumatoid arthritis of an individual is disclosed. The method comprises the step of expressing within the individual at least an immunologically recognizable portion of a cytokine from an exogenous polynucleotide encoding the at least a portion of the cytokine, wherein a level of expression of the at least a portion of the cytokine is sufficient to induce the formation of anti-cytokine immunoglobulins which serve for neutralizing or ameliorating the activity of a respective and/or cross reactive endogenous cytokine, to thereby treat rheumatoid arthritis.Type: ApplicationFiled: August 6, 2002Publication date: May 6, 2004Inventor: Nathan Karin
-
Publication number: 20040086484Abstract: The invention is intended to adapt an already established clinical procedure for the treatment of multiple sclerosis (MS)—the use of beta interferon—to treat chronic human spinal cord injury. The present invention relates to the prevention of chronic inflammation and demyelination following spinal cord injury.Type: ApplicationFiled: October 24, 2003Publication date: May 6, 2004Inventor: Nurit Kalderon
-
Publication number: 20040086485Abstract: A nucleic acid sequence in a plasmid form comprising all the necessary elements for the production of a viral vector and this plasmid is delivered in-vivo with the intent of in-vivo viral vector production. The delivery of this vector may be further directed to specific targeted tissues by the addition of conjugated molecules, such as polycations, peptides, antibodies, single chain antibodies or combinations of the above.Type: ApplicationFiled: October 4, 2002Publication date: May 6, 2004Inventor: Carlos Estuardo Aguilar-Cordova
-
Publication number: 20040086486Abstract: The invention provides methods and compositions for increasing the delivery of nucleic acids into a host by administering a nucleic acid encoding a therapeutic nucleic acid along with an agent that modulates Kupffer cell function in the host.Type: ApplicationFiled: July 11, 2003Publication date: May 6, 2004Inventors: James G. Barsoum, Michael Parr, Stephen E. Fawell
-
Publication number: 20040086487Abstract: A method of inducing blood vessel formation in an animal by administering to the animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof. The polynucleotide may be contained in an appropriate expression vector, such as a viral vector. The delivery of sphingosine kinase through administration of an expression vector which expresses sphingosine kinase provides for the formation of larger blood vessels containing a well defined structure that is supported by mural cells such as pericytes and smooth muscle cells.Type: ApplicationFiled: July 14, 2003Publication date: May 6, 2004Applicant: Novartis AGInventors: Gene Liau, Steingrimur Stefansson, Joseph Su
-
Publication number: 20040086488Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.Type: ApplicationFiled: September 11, 2003Publication date: May 6, 2004Inventors: Alan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous
-
Publication number: 20040086489Abstract: The invention provides compositions containing modified cytomegalovirus, and methods of using the compositions. In various embodiments, the modifications include adding a heterologous sequence encoding a non-viral chemokine element and/or immunogenic polypeptide, and/or disabling a viral dissemination gene.Type: ApplicationFiled: October 8, 2003Publication date: May 6, 2004Applicant: ChemoCentryx, Inc.Inventors: Thomas J. Schall, Mark E.T. Penfold
-
Publication number: 20040086490Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: ApplicationFiled: November 20, 2003Publication date: May 6, 2004Applicant: Sumesh KaushalInventors: John A. Chiorini, Robert M. Kotin, Brian Safer
-
Publication number: 20040086491Abstract: A prebiotic, composition comprising a probiotic and prebiotic, and method of delivering a probiotic, prebiotic or composition directly into the intestinal tract of a mammal are disclosed. The probiotic is any beneficial bacteria and the prebiotic is a substance beneficial to a probiotic. Most preferably, the prebiotic includes a mucopolysaccharide. The method preferably involves delivering the probiotic, prebiotic or composition via a delivery tube, such as an enteral feeding tube, directly to a position downstream of the stomach, most preferably to the jejunum.Type: ApplicationFiled: February 5, 2002Publication date: May 6, 2004Applicant: Corpak MedSystems, Inc.Inventor: Woodrow C. Monte
-
Publication number: 20040086492Abstract: A treatment method more effective in treating tumors such as cancer by administering activated lymphocytes in combination with a photodynamic therapy procedure within a specific period of time preceding or following the procedure is provided. By treating the patient with the combination of PDT procedure and the activated lymphocyte administration, a remarkable effect is achieved in reducing and suppressing various types of tumors, including stomach cancer in particular, and also desirable results are achieved even when tumors not responsive to PDT procedure alone are treated in this manner, due to the synergy of the PDT procedure and the activated lymphocyte administration. Provided that the activated lymphocytes are used in combination with a PDT procedure, even activated lymphocytes not necessarily achieving cancer specificity can be expected to improve the treatment effect in destroying or suppressing the growth of tumors such as cancers.Type: ApplicationFiled: September 5, 2003Publication date: May 6, 2004Inventors: Hideo Yanai, Kiwamu Okita, Yasuyuki Kuroiwa, Teruaki Sekine
-
Publication number: 20040086493Abstract: Water soluble macromers are modified by addition of free radical polymerizable groups, such as those containing a carbon-carbon double or triple bond, which can be polymerized under mild conditions to encapsulate tissues, cells, or biologically active materials. The polymeric materials are particularly useful as tissue adhesives, coatings for tissue lumens including blood vessels, coatings for cells such as islets of Langerhans, coatings, plugs, supports or substrates for contact with biological materials such as the body, and as drug delivery devices for biologically active molecules.Type: ApplicationFiled: June 25, 2003Publication date: May 6, 2004Applicant: Board of Regents, The University of Texas SystemInventors: Jeffrey A. Hubbell, Chandrashekhar P. Pathak, Amarpreet S. Sawhney, Neil P. Desai, Jennifer L. Hill, Syed F.A. Hossainy
-
Publication number: 20040086494Abstract: Methods for sustained delivery of biologically active proteins or peptides to mammals are disclosed. Specific types of immune-privileged allogeneic or xenogenic donor cells that are naturally immune privileged are genetically modified in vitro to express or secrete the proteins or peptides. The genetically modified donor cells are subsequently implanted into host mammals and utilized for sustained delivery of biologically active proteins or peptides in vivo. The donor cells so utilized are those that inherently possess immune privilege due at least partly to the expression of Fas ligand. Methods for cell isolation, purification, tissue culture expansion, cryopreservation, gene transfer, transgene and Fas ligand expression, cell implantation, and measurement of immune responses of host animals are described.Type: ApplicationFiled: August 28, 2001Publication date: May 6, 2004Inventor: Constance Mary John
-
Publication number: 20040086495Abstract: The invention refers to a method for the prevention of arteriosclerosis or the reduction of the arteriosclerosis risk, by purposefully effecting the phosphorylation status of BAD.Type: ApplicationFiled: July 5, 2002Publication date: May 6, 2004Applicant: EUCRO EUROPEAN CONTRACT RESEARCH GMBH & CO. KGInventors: Josef Kriegelstein, Susanne Klumpp
-
Publication number: 20040086496Abstract: The invention provides a novel composition and methods of its preparation and uses. The composition comprises as main components serum and a gelling agent and is useful in various medical applications. The composition may be used to coat a medical device, as a biological glue, or as dressings, membranes, scaffolding or hydrogel useful in bioengineering applications. One or more therapeutic products may be added to the composition and the composition is also a vehicle for delivery of therapeutic products.Type: ApplicationFiled: November 4, 2002Publication date: May 6, 2004Applicants: National University of Singapore, National Heart CenterInventors: Vijay Gopal Reddy Peddareddigari, Tai Tian Lim, Reida Menshawe El Oakley
-
Publication number: 20040086497Abstract: Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.Type: ApplicationFiled: October 21, 2003Publication date: May 6, 2004Inventors: David T. MacLaughlin, Joseph P. Vacanti, Patricia K. Donahoe, Peter T. Masiakos
-
Publication number: 20040086498Abstract: A method is provided for treating mammals, including humans, with advanced or large-tumour burdens. The method involves administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present. In preferred embodiments, the immunotherapeautic agent comprises a T-cell co-stimulatory cell adhesion molecule (CAM) or a mammalian expression vector containing DNA which encodes a T-cell co-stimulatory CAM, such as B7.1, and the tumour growth restricting agent is flavone acetic acid, 5,6-dimenthyl-xanthenone-4-acetic acid, or an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).Type: ApplicationFiled: December 11, 2001Publication date: May 6, 2004Inventors: Geoffrey W. Krissansen, Jagat Rakesh Kanwar, Lai-Ming Ching
-
Publication number: 20040086499Abstract: The present invention generally relates to a method of immobilising molecules or particles on the surface of hydrophobic polymeric materials, wherein said immobilisation is mediated by a mucin layer adsorbed to said surface. More particularly the invention relates to such a method, wherein the polymeric material is a biomaterial for in vivo applications. The present invention also relates to a hydrophobic polymeric substrate provided with a mucin layer having selected molecules and/or particles immobilised thereto, obtainable by means of the method, and a biocompatible highly specific binding system comprising a mucin and a lectin or a functional fragment of a lectin, which system can be used in the method.Type: ApplicationFiled: October 22, 2003Publication date: May 6, 2004Inventors: Karin Dahlgren Caldwell, Tomas Sandberg, Lei Shi, Maria Werner, Matti J. Nikkola
-
Publication number: 20040086500Abstract: The invention concerns a novel 116 kDa polypeptide exhibiting homologies of sequences with RNA helicases (DEXH box) called RH116 and its fragments, the cloning of cDNA and the polynucleotides encoding said polypeptides, cloning and/or expression vectors including said polynucleotides, cells transformed by said vectors and specific antibodies directed against said polypeptides. The invention also concerns methods for detecting and/or assaying said polypeptides and polynucleotides, corresponding diagnosis kits, and a method for screening ligands, as well as compounds for use as medicine for preventing and/or therapeutic treatment.Type: ApplicationFiled: September 12, 2003Publication date: May 6, 2004Inventors: Georges Bahr, Cecile Cocude, Andre Capron
-
Publication number: 20040086501Abstract: BTL.012 is a novel human protein useful for regulating or modulating angiogenesis. BTL.012, or variants thereof, may be employed as therapeutics in diseases such as cancer, wound healing, diabetic retinopathies, macular degeneration, and cardiovascular diseases, and other diseases or clinical conditions where angiogenesis is relevant to the causation or treatment of the disease.Type: ApplicationFiled: May 31, 2002Publication date: May 6, 2004Inventor: Gayle Delmonte Wetzel
-
Publication number: 20040086502Abstract: Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.Type: ApplicationFiled: July 21, 2003Publication date: May 6, 2004Applicant: Genentech, Inc.Inventors: Yvonne M. Chen, Henry B. Lowman, Yves Muller
-
Publication number: 20040086503Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: January 4, 2002Publication date: May 6, 2004Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
-
Publication number: 20040086504Abstract: The present invention contemplates methods of preventing or inhibiting breast cancer cell proliferation, compounds and compositions that interfere with or block sex steroid or growth factor binding to and induction of the Cyr61 gene and methods of screening ligands that regulate Cyr61 protein expression. The present invention further contemplates compounds that block Cyr61 activity. The invention further relates to methods of diagnosing and staging patients with cancers associated with an upregulation of Cyr61 expression. Assay methods and kits are also disclosed.Type: ApplicationFiled: September 10, 2003Publication date: May 6, 2004Inventors: Deepak Sampath, Zhiming Zhang, Richard Winneker
-
Publication number: 20040086505Abstract: The present invention provides a human-derived protein or a salt thereof, a DNA encoding the same, a method for determination of ligand to the protein, a screening method/kits for a compound or its salt that alters a binding property between ligand and the protein, and the like. The human-derived protein or a DNA encoding the same of the present invention can be used in (1) determination of ligand to the protein of the present invention, (2) a prophylactic/therapeutic agent for diseases associated with dysfunction of the protein of the present invention, (3) a screening of a compound (agonist, antagonist, etc.) that alters a binding property between the protein and the ligand of the present invention, and the like.Type: ApplicationFiled: January 6, 2003Publication date: May 6, 2004Inventors: Takeo Moriya, Takashi Ito, Yasushi Shintani, Nobuyuki Miyajima
-
Publication number: 20040086506Abstract: The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method.Type: ApplicationFiled: May 8, 2003Publication date: May 6, 2004Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, Bette T. Korber, Robert M. De Lorimier, Hua-Xin Liao
-
Publication number: 20040086507Abstract: There is provided an antibody which specifically recognizes protein comprising an amino acid sequence represented by SEQ ID NO: 1 and inhibits the growth factor activity of the said protein.Type: ApplicationFiled: April 18, 2003Publication date: May 6, 2004Inventors: Kenya Shitara, Akiko Furuya
-
Publication number: 20040086508Abstract: The present invention comprises and utilizes methods and compositions for treating organ and cell transplant rejection. Compositions comprising antibodies to gamma interferon and tumor necrosis factor alone, together, and in combination with other drugs are described. Further disclosed are methods of treating organ transplant rejection comprising the administration of antibodies to cytokine receptors, soluble receptors, and extracorporeal removal of cytokines and other autoimmune mediators.Type: ApplicationFiled: July 30, 2003Publication date: May 6, 2004Applicant: Advanced Biotherapy, Inc.Inventors: Boris Skurkovich, Simon Skurkovich
-
Publication number: 20040086509Abstract: The present invention provides testis-specific insulin homolog polypeptides and polynucleotides encoding the polypeptides, as well as related compositions and methods are disclosed. The polypeptides and polynucleotides may be used within methods for enhancing viability of cryopreserved sperm, for enhancing sperm motility, to enhance fertilization in methods of assisted reproduction, as contraceptives and other related uses.Type: ApplicationFiled: November 3, 2003Publication date: May 6, 2004Applicant: ZymoGenetics, Inc.Inventors: Si Lok, Darrell C. Conklin, Catherine E. Lofton-Day
-
Publication number: 20040086510Abstract: It is an object of the present invention to provide an IRAP-binding protein. Specifically, the present invention provides the IRAP-binding protein, pharmaceuticals comprising the protein, a method for screening a compound inhibiting binding of the protein to IRAP, and a compound obtained by the screening method.Type: ApplicationFiled: October 9, 2003Publication date: May 6, 2004Inventors: Hideaki Tojo, Nozomu Katayama, Shigeya Kakimoto
-
Publication number: 20040086511Abstract: Neuronal cell death, as modeled by removal of serum or NGF from growth medium, is characterized by many changes in gene expression. Gene expression was compared before and after withdrawal of serum or NGF. These results provide clues to underlying molecular processes occurring during neuronal and photoreceptor degeneration, and provide direction for future cell-based studies.Type: ApplicationFiled: July 14, 2003Publication date: May 6, 2004Applicant: The Johns Hopkins UniversityInventors: Donald Jeffery Zack, Masaaki Kageyama
-
Publication number: 20040086512Abstract: One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle.Type: ApplicationFiled: October 17, 2003Publication date: May 6, 2004Applicant: Thomas Jefferson UniversityInventors: Hui Zhang, Roger J. Pomerantz, Bin Yang
-
Publication number: 20040086513Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.Type: ApplicationFiled: November 12, 2003Publication date: May 6, 2004Inventors: John M. Fairbrother, Josee Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
-
Publication number: 20040086514Abstract: Helicobacter pylori-binding substances comprising Gal&bgr;3GlcNAc or Gal&bgr;3GalNAc are described, as well as use thereof in pharmaceutical compositions and food-stuff, and methods for treatment of conditions due to the presence of Helicobacter pylori. Also use of said substance for the identification of bacterial adhesions, for the production of a vaccine against Helicobacter pylori, for diagnosis of Helicobacter pylori infections, for typing of Helicobacter pylori, for identification of Helicobacter pylori binding substances and for inhibition of the binding of Helicobacter pylori is described.Type: ApplicationFiled: June 14, 2002Publication date: May 6, 2004Inventors: Karl-Anders Karlsson, Irene Leonardsson, Susann Teneberg, Jonas Angstrom
-
Publication number: 20040086515Abstract: Sickle-cell diseases are treated with annexin proteins that are modified to increase their half-life in the circulation.Type: ApplicationFiled: August 1, 2003Publication date: May 6, 2004Applicant: SurroMed, Inc.Inventor: Anthony Allison
-
Publication number: 20040086516Abstract: We describe (1) a method of enhancing antigen presentation, comprising the step of supplying to an antigen presenting cell such as a dendritic cell, or precursor cell, an inhibitor of Toll-related receptor (TRR) signalling and (2) a method of inhibiting antigen presentation, comprising the step of supplying to an antigen presenting cell such as a dendritic cell, or precursor cell, an enhancer of Toll-related receptor (TRR) signalling. The inhibitor of TRR signalling may be a dominant negative mutant of MyD88, for example MyD881pr.Type: ApplicationFiled: October 10, 2003Publication date: May 6, 2004Inventors: Brian Maurice John Foxwell, Marc Feldmann
-
Publication number: 20040086517Abstract: The present invention is directed to an implantable immune modulation device that is useful for modulating an immune response in mammals, comprising a plurality of fibers, within a porous shell. The fiber filling is loaded with single or multiple antigens, and optionally one or more biologically active compounds such as cytokines (e.g. lymphokines, chemokines etc.), attachment factors, genes, peptides, proteins, nucleotides, carbohydrates or cells depending on the application.Type: ApplicationFiled: June 24, 2003Publication date: May 6, 2004Inventors: Kevor S. TenHuisen, Joe Rosenblatt, Ilya S. Koyfman
-
Publication number: 20040086518Abstract: A universal cancer vaccine Having at least one telomerase reverse transcriptase peptide as a specific tumor antigen, a method for its use for targeting cytotoxic T lymphocytes to tumor cells, and a method for induction and/or augmentation of a cancer patient's immune response against his tumor are disclosed.Type: ApplicationFiled: February 15, 2001Publication date: May 6, 2004Inventor: Maurizio Zanetti
-
Publication number: 20040086519Abstract: The present invention relates to methods and compositions for the modulation of restenosis and stenosis characterized by constrictive vascular remodeling and neointimal formation, in a subject, by administering a P-selectin antagonist. The invention further provides methods for modulating leukocyte recruitment, cell to cell adhesion, and cell adhesion to blood vessels in a subject by administering soluble P-selectin ligand, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. The invention also provides methods for identifying compounds capable of modulating restenosis.Type: ApplicationFiled: May 7, 2003Publication date: May 6, 2004Applicants: Genetics Institute, LLC, Montreal Heart Institute of MontrealInventors: Anjali Kumar, Robert G. Schaub, Jean-Francois Tanguay, Yahye Merhi
-
Publication number: 20040086520Abstract: We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence.Type: ApplicationFiled: August 20, 2003Publication date: May 6, 2004Applicant: City of HopeInventor: Don J. Diamond
-
Publication number: 20040086521Abstract: Antigenic peptides may be isolated from a limited quantity of cells or bodily fluid from a mammalian organism in an amount sufficient to determine their sequence and identity. Therefore this invention relates to methods for identifying novel disease-associated antigens, e.g. tumor antigens and antigens involved in autoimmune diseases, to be utilized for diagnostic or therapeutic purposes. The methods of the present invention can also be utilized for controlling the quality of vaccines. More specifically, the methods of the invention can be used for determining the sequence of antigenic peptides presented via peptide receptors of dendritic cells which are the most important antigen presenting cells of the body and valuable tools for vaccination.Type: ApplicationFiled: October 1, 2003Publication date: May 6, 2004Inventors: Harald Kropshofer, Anne Vogt
-
Publication number: 20040086522Abstract: Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease.Type: ApplicationFiled: June 27, 2003Publication date: May 6, 2004Applicant: Oklahoma Medical Research FoundationInventors: John B. Harley, Judith A. James
-
Publication number: 20040086523Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.Type: ApplicationFiled: June 20, 2001Publication date: May 6, 2004Inventors: Yasir Skeiky, Steven Reed, Mark Alderson
-
Publication number: 20040086524Abstract: The use of the 17 kDa outer surface lipoprotein (OspA) of Piscirickettsia salmonis, or its homologues, as the basis of, or part thereof, a recombinant vaccine for salmonid rickettsial septicaemia and other rickettsial diseases is disclosed. Surface antigens of the bacterial pathogen P. salmonis are characterized and an immunoreactive antigen, namely the 17 kDa outer surface lipoprotein OspA of P. salmonis, as well as the nucleic acid segment that encodes the OspA immunoreactive antigen, is identified and characterized. Diagnostic techniques including the use of hybridization probes and primers as well as the production of specific antigens and antibodies that may be used in immunization techniques for inducing immunity against P. salmonis and other rickettsial diseases are disclosed, as are the development of recombinant vaccines for SRS and other rickettsial diseases based on the 17 kDa lipoprotein OspA.Type: ApplicationFiled: September 30, 2002Publication date: May 6, 2004Inventors: Michael A. Kuzyk, Jan Burian, William W. Kay, Julian C. Thornton